BIOLIFE SOLUTIONS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
BLFS$38.61+3.5%Stored close · as of Oct 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31 | |||
|---|---|---|---|
| (In thousands, except per share and share data) | 2023 | 2022 | 2021 |
| Product revenue | $117,695 | $136,000 | $101,913 |
| Service revenue | 17,551 | 15,308 | 9,817 |
| Rental revenue | 8,025 | 10,451 | 7,426 |
| Total product, service, and rental revenue | 143,271 | 161,759 | 119,156 |
| Costs and operating expenses: | |||
| Cost of product revenue (exclusive of intangible assets amortization) | 75,751 | 88,519 | 69,676 |
| Cost of service revenue (exclusive of intangible assets amortization) | 15,586 | 12,360 | 5,381 |
| Cost of rental revenue (exclusive of intangible assets amortization) | 5,182 | 7,058 | 7,051 |
| General and administrative | 55,725 | 47,670 | 33,668 |
| Sales and marketing | 24,583 | 21,570 | 14,006 |
| Research and development | 18,796 | 14,798 | 11,821 |
| Asset impairment charges | 15,485 | 110,364 | — |
| Intangible asset amortization | 5,181 | 9,697 | 8,202 |
| Acquisition costs | — | 18 | 1,636 |
| Change in fair value of contingent consideration | (2,193) | (4,754) | 2,875 |
| Total operating expenses | 214,096 | 307,300 | 154,316 |
| Operating loss | (70,825) | (145,541) | (35,160) |
| Other income: | |||
| Change in fair value of warrant liability | — | — | (121) |
| Change in fair value of investments | — | 697 | — |
| Interest expense, net | (1,812) | (687) | (485) |
| Other income | 1,264 | 704 | 289 |
| Gain on settlement of Global Cooling escrow | 5,115 | — | — |
| Gain on acquisition of Sexton Biotechnologies, Inc. | — | — | 6,451 |
| Total other income, net | 4,567 | 714 | 6,134 |
| Loss before income tax (expense) benefit | (66,258) | (144,827) | (29,026) |
| Income tax (expense) benefit | (169) | 5,022 | 20,118 |
| Net loss | $(66,427) | $(139,805) | $(8,908) |
| Net loss attributable to common shareholders: | |||
| Basic and Diluted | $(66,427) | $(139,805) | $(8,908) |
| Net loss per share attributable to common shareholders: | |||
| Basic and Diluted | $(1.52) | $(3.29) | $(0.23) |
| Weighted average shares used to compute loss per share attributable to common shareholders: | |||
| Basic and Diluted | 43,719,185 | 42,481,027 | 38,503,944 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.